Wednesday, 4 April 2012

Hyoscyamine Sulfate Orally Disintegrating Tablet




Generic Name: hyoscyamine sulfate

Dosage Form: tablet, orally disintegrating
Hyoscyamine Sulfate Orally Disintegrating Tablets, 0.125 mg

PI-9324

Rev 02/09     Rx Only

Hyoscyamine Sulfate Orally Disintegrating Tablet Description


Hyoscyamine Sulfate Orally Disintegrating Tablets contain 0.125 mg hyoscyamine sulfate formulated for oral administration. Hyoscyamine Sulfate Orally Disintegrating Tablets 0.125 mg disintegrate within seconds after placement on the tongue, allowing them to be swallowed with or without water.


Hyoscyamine sulfate is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids. The empirical formula is (C17H23NO3)2•H2SO4•2H2O and the molecular weight is 712.85. Chemically, it is benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1] oct-3-yl ester, [3(S)-endo]-, sulfate (2:1), dihydrate with the following structure:



Each tablet also contains as inactive ingredients: colloidal silicon dioxide, crospovidone, magnesium stearate, mannitol, sorbitol and flavor.



Hyoscyamine Sulfate Orally Disintegrating Tablet - Clinical Pharmacology


Hyoscyamine sulfate inhibits specifically the actions of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of the smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node and the exocrine glands. At therapeutic doses, it is completely devoid of any action on the autonomic ganglia. Hyoscyamine sulfate inhibits gastrointestinal propulsive motility and decreases gastric acid secretion. Hyoscyamine sulfate also controls excessive pharyngeal, tracheal and bronchial secretions.


Hyoscyamine sulfate is absorbed totally and completely by oral administration. Once absorbed, hyoscyamine sulfate disappears rapidly from the blood and is distributed throughout the entire body. The half-life of hyoscyamine sulfate is 2 to 3 1/2 hours. Hyoscyamine sulfate is partly hydrolyzed to tropic acid and tropine but the majority of the drug is excreted in the urine unchanged within the first 12 hours. Only traces of this drug are found in breast milk. Hyoscyamine sulfate passes the blood brain barrier and the placental barrier.



Indications and Usage for Hyoscyamine Sulfate Orally Disintegrating Tablet


Hyoscyamine Sulfate Orally Disintegrating Tablets are effective as adjunctive therapy in the treatment of peptic ulcer. They can also be used to control gastric secretions, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm and associated abdominal cramps. May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis and acute enterocolitis. For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. Also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Hyoscyamine Sulfate Orally Disintegrating Tablets are indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic; as a “drying agent” in the relief of symptoms of acute rhinitis; in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis. May be used in the therapy of poisoning by anticholinesterase agents.



Contraindications


Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis); paralytic ileus, intestinal atony of elderly or debilitated patients; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.



Warnings


In the presence of high environmental temperature, heat prostration can occur with drug use (fever and heat stroke due to decreased sweating). Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful. Like other anticholinergic agents, hyoscyamine sulfate may produce drowsiness, dizziness or blurred vision. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug.


Psychosis has been reported in sensitive individuals given anticholinergic drugs including hyoscyamine sulfate. CNS signs and symptoms include confusion, disorientation, short-term memory loss, hallucinations, dysarthria, ataxia, coma, euphoria, anxiety, decreased anxiety, fatigue, insomnia, agitation and mannerisms and inappropriate affect. These CNS signs and symptoms usually resolve within 12 to 48 hours after discontinuation of the drug.



Precautions



General:


Use with caution in patients with: autonomic neuropathy, hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, hypertension and renal disease. Investigate any tachycardia before giving any anticholinergic drugs since they may increase the heart rate. Use with caution in patients with hiatal hernia associated with reflux esophagitis.



Information for Patients:


Like other anticholinergic agents, hyoscyamine sulfate may produce drowsiness, dizziness or blurred vision. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug.


Use of hyoscyamine sulfate may decrease sweating resulting in heat prostration, fever or heat stroke; febrile patients or those who may be exposed to elevated environmental temperatures should use caution.



Drug Interactions:


Additive adverse effects resulting from cholinergic blockade may occur when hyoscyamine sulfate is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.


Antacids may interfere with the absorption of hyoscyamine sulfate. Administer Hyoscyamine Sulfate Orally Disintegrating Tablets before meals; antacids after meals.



Carcinogenesis, Mutagenesis, Impairment of Fertility:


No long-term studies in animals have been performed to determine the carcinogenic, mutagenic or impairment of fertility potential of hyoscyamine sulfate; however, 40 years of marketing experience with hyoscyamine sulfate shows no demonstrable evidence of a problem.



Pregnancy-Pregnancy Category C:


Animal reproduction studies have not been conducted with hyoscyamine sulfate. It is also not known whether hyoscyamine sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Hyoscyamine Sulfate Orally Disintegrating Tablets should be given to a pregnant woman only if clearly needed.



Nursing Mothers:


Hyoscyamine sulfate is excreted in human milk. Caution should be exercised when Hyoscyamine Sulfate Orally Disintegrating Tablets are administered to a nursing woman.



Geriatric Use:


Reported clinical experience has not identified differences in safety between patients aged 65 and over and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.


This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.



Adverse Reactions


The following adverse reactions have been reported for hyoscyamine sulfate and for pharmacologically similar drugs with anticholinergic/antispasmodic action. Adverse reactions may include dryness of the mouth; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; mydriasis; cycloplegia; increased ocular tension; loss of taste; headache; nervousness; drowsiness; weakness; fatigue; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; abdominal pain; diarrhea; allergic reactions or drug idiosyncrasies; urticaria and other dermal manifestations; ataxia; speech disturbance; some degree of mental confusion and/or excitement (especially in elderly persons); short-term memory loss; hallucinations; and decreased sweating.



Overdosage


The signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils, hot dry skin, dizziness, dryness of the mouth, difficulty in swallowing and CNS stimulation.


Measures to be taken are immediate lavage of the stomach and injection of physostigmine 0.5 to 2 mg intravenously and repeated as necessary up to a total of 5 mg. Fever may be treated symptomatically (tepid water sponge baths, hypothermic blanket). Excitement to a degree which demands attention may be managed with sodium thiopental 2% solution given slowly intravenously or chloral hydrate (100-200 mL of a 2% solution) by rectal infusion. In the event of progression of the curare-like effect to paralysis of the respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns.


In rats, the LD50 for hyoscyamine is 375 mg/kg. Hyoscyamine sulfate is dialyzable.



Hyoscyamine Sulfate Orally Disintegrating Tablet Dosage and Administration


Dosage may be adjusted according to the conditions and severity of symptoms. Place a Hyoscyamine Sulfate Orally Disintegrating Tablet on tongue, allowing the tablet to rapidly disintegrate and be swallowed. May be taken with or without water.


Adults and pediatric patients 12 years of age and older: 1 to 2 tablets every four hours or as needed. Do not exceed 12 tablets in 24 hours.


Pediatric patients 2 to under 12 years of age: 1/2 to 1 tablet every four hours or as needed. Do not exceed 6 tablets in 24 hours.



How is Hyoscyamine Sulfate Orally Disintegrating Tablet Supplied


Hyoscyamine Sulfate Orally Disintegrating Tablets 0.125 mg are white, round, flat-faced, beveled edge, mint flavored tablets debossed with “CL” on one side and “12” on the other.


Bottles of 100


NDC 43199-012-01


Store at controlled room temperature 20°-25°C (68°-77°F); excursion permitted to 15°-30°C (59°-86°F). Please refer to current USP.


Dispense in tight, light-resistant containers as defined in USP/NF with a child-resistant closure.


KEEP OUT OF REACH OF CHILDREN



Manufactured for:


County Line Pharmaceuticals, LLC

Brookfield, WI 53005


For inquiries call toll free 1-866-207-5636.


PI-9324

Rev 02/09



PRINCIPAL DISPLAY PANEL



NDC 43199-012-01


100 Tablets


Hyoscyamine Sulfate Orally Disintegrating Tablets


0.125 mg


Rx Only


Each Tablet contains 0.125 mg hyoscyamine sulfate, USP.


USUAL DOSAGE: 

See package insert for full prescribing information.


Dispense in tight, light-resistant containers as defined in USP/NF with a child-resistant closure.


Store at controlled room temperature 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). Please refer to current USP.









HYOSCYAMINE SULFATE 
hyoscyamine sulfate  tablet, orally disintegrating










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)43199-012
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
HYOSCYAMINE SULFATE (HYOSCYAMINE)HYOSCYAMINE SULFATE0.125 mg














Inactive Ingredients
Ingredient NameStrength
SILICON DIOXIDE 
CROSPOVIDONE 
MAGNESIUM STEARATE 
MANNITOL 
SORBITOL 


















Product Characteristics
ColorWHITEScoreno score
ShapeROUNDSize7mm
FlavorMINTImprint CodeC;12
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
143199-012-01100 TABLET In 1 BOTTLENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug other09/21/2009


Labeler - County Line Pharmaceuticals, LLC (015585278)









Establishment
NameAddressID/FEIOperations
ANIP Acquistion Company831049809ANALYSIS, MANUFACTURE
Revised: 01/2010County Line Pharmaceuticals, LLC

More Hyoscyamine Sulfate Orally Disintegrating Tablet resources


  • Hyoscyamine Sulfate Orally Disintegrating Tablet Side Effects (in more detail)
  • Hyoscyamine Sulfate Orally Disintegrating Tablet Dosage
  • Hyoscyamine Sulfate Orally Disintegrating Tablet Use in Pregnancy & Breastfeeding
  • Drug Images
  • Hyoscyamine Sulfate Orally Disintegrating Tablet Drug Interactions
  • Hyoscyamine Sulfate Orally Disintegrating Tablet Support Group
  • 20 Reviews for Hyoscyamine Sulfate Orally Disintegrating - Add your own review/rating


Compare Hyoscyamine Sulfate Orally Disintegrating Tablet with other medications


  • Anesthesia
  • Crohn's Disease
  • Endoscopy or Radiology Premedication
  • Irritable Bowel Syndrome
  • Urinary Incontinence

Monday, 2 April 2012

Sectral


Pronunciation: A-se-BUE-toe-lol
Generic Name: Acebutolol
Brand Name: Sectral


Sectral is used for:

Treating high blood pressure. It may be used alone or in combination with other medicines. It is also used to treat certain kinds of irregular heartbeat. It may also be used for other conditions as determined by your doctor.


Sectral is a beta-blocker. It works by causing the heart to beat more slowly and regularly.


Do NOT use Sectral if:


  • you are allergic to any ingredient in Sectral

  • you have a very slow heart rate, active heart failure, heart block, shock caused by serious heart problems, or low blood pressure caused by a heart attack

  • you are taking mibefradil

Contact your doctor or health care provider right away if any of these apply to you.



Before using Sectral:


Some medical conditions may interact with Sectral. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have heart failure, other heart problems (eg, slow heart rate, valve disease, ventricular problems), low blood pressure, or blood vessel problems (eg, narrowing of the blood vessels)

  • if you have breathing or lung problems (eg, bronchitis, asthma, chronic obstructive pulmonary disease), diabetes, an overactive thyroid, liver or kidney problems, or adrenal gland problems (eg, pheochromocytoma)

  • if you are currently having a severe allergic reaction or if you have a history of any severe allergic reaction

  • if you will be having surgery

Some MEDICINES MAY INTERACT with Sectral. Tell your health care provider if you are taking any other medicines, especially the following:


  • Digoxin, diltiazem, disopyramide, fingolimod, flecainide, ketanserin, mibefradil, or reserpine because side effects, such as severe low blood pressure or slow heart rate, may occur

  • Mefloquine or verapamil because the risk of serious heart problems may be increased

  • Certain cold medicines, decongestant nasal sprays (eg, oxymetazoline), or diet medicines because severe high blood pressure may occur

  • Clonidine because high blood pressure may occur in some cases, especially if you suddenly stop taking clonidine while taking Sectral

  • Indomethacin or nonsteroidal anti-inflammatory drugs (NSAIDs) (eg, ibuprofen) because they may decrease Sectral's effectiveness

  • Flecainide, hydralazine, ketanserin, or quinazolines (eg, alfuzosin) because the risk of their side effects may be increased by Sectral

This may not be a complete list of all interactions that may occur. Ask your health care provider if Sectral may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Sectral:


Use Sectral as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Sectral by mouth with or without food.

  • Taking Sectral at the same time each day will help you remember to take it.

  • Continue to take Sectral even if you feel well. Do not miss any doses.

  • If you miss a dose of Sectral, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Sectral.



Important safety information:


  • Sectral may cause drowsiness, dizziness, or lightheadedness. These effects may be worse if you take it with alcohol or certain medicines. Use Sectral with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Sectral may cause dizziness, lightheadedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.

  • Patients who take medicine for high blood pressure often feel tired or run down for a few weeks after starting treatment. Be sure to take your medicine even if you may not feel "normal." Tell your doctor if you develop any new symptoms.

  • Diabetes patients - Sectral may hide signs of low blood sugar, such as a rapid heartbeat. Be sure to watch for other signs of low blood sugar. Low blood sugar may make you anxious, sweaty, weak, dizzy, drowsy, or faint. It may also make your vision change; give you a headache, chills, or tremors; or make you more hungry. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.

  • Do not suddenly stop taking Sectral. Sharp chest pain, irregular heartbeat, and sometimes a heart attack may occur if you suddenly stop Sectral. The risk may be greater if you have certain types of heart disease. Your doctor should slowly lower your dose over several weeks if you need to stop taking it. This should be done even if you only take Sectral for high blood pressure. Heart disease is common and you may not know you have it. Limit physical activity while you are lowering your dose. If new or worsened chest pain or other heart problems occur, contact your doctor right away. You may need to start taking Sectral again.

  • If you have a history of any severe allergic reaction, talk with your doctor. You may be at risk of an even more severe allergic reaction if you come into contact with the substance that caused your allergy. Some medicines used to treat severe allergies may also not work as well while you are using Sectral.

  • If you have high blood pressure, do not use nonprescription products that contain stimulants. These products may include diet pills or cold medicines, including nasal sprays. Contact your doctor if you have any questions or concerns.

  • If your doctor has instructed you to check your blood pressure and heart rate regularly, be sure to do so.

  • Tell your doctor or dentist that you take Sectral before you receive any medical or dental care, emergency care, or surgery.

  • Use Sectral with caution in the ELDERLY; they may be more sensitive to its effects.

  • Sectral should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Sectral while you are pregnant. Sectral is found in breast milk. Do not breast-feed while taking Sectral.


Possible side effects of Sectral:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Constipation; diarrhea; dizziness or lightheadedness; frequent urination; gas; headache; indigestion; mild drowsiness; nausea; sleepiness; sleeplessness; unusual tiredness or weakness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain or tightness; dark urine; difficulty breathing, especially when lying down; mental or mood changes; pale stools; persistent muscle or joint pain; persistent nausea or loss of appetite; shortness of breath; swelling of the hands, ankles, or feet; unusually slow heartbeat; yellowing of the skin or eyes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Sectral side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include difficulty breathing, especially when lying down; fainting; lightheadedness, especially when standing; seizures (convulsions); shortness of breath; swelling of ankles; very slow heart rate; weakness; wheezing.


Proper storage of Sectral:

Store Sectral at room temperature, between 68 and 77 degrees F (20 and 25 degrees C), in a tightly closed container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Sectral out of the reach of children and away from pets.


General information:


  • If you have any questions about Sectral, please talk with your doctor, pharmacist, or other health care provider.

  • Sectral is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is summary only. It does not contain all information about Sectral. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Sectral resources


  • Sectral Side Effects (in more detail)
  • Sectral Use in Pregnancy & Breastfeeding
  • Drug Images
  • Sectral Drug Interactions
  • Sectral Support Group
  • 0 Reviews for Sectral - Add your own review/rating


  • Sectral Prescribing Information (FDA)

  • Sectral Advanced Consumer (Micromedex) - Includes Dosage Information

  • Sectral Concise Consumer Information (Cerner Multum)

  • Sectral Monograph (AHFS DI)

  • Acebutolol Prescribing Information (FDA)



Compare Sectral with other medications


  • High Blood Pressure
  • Premature Ventricular Depolarizations
  • Ventricular Tachycardia

Sunday, 1 April 2012

Papain/Urea Foam


Pronunciation: pa-PAY-in/ue-REE-a
Generic Name: Papain/Urea
Brand Name: Paptase


Papain/Urea Foam is used for:

Removing dead tissue and thinning the pus in lesions such as ulcers, burns, wounds, and carbuncles.


Papain/Urea Foam is a debriding agent. It works by helping the breakdown of dead skin and pus, which helps improve the recovery time of open wounds.


Do NOT use Papain/Urea Foam if:


  • you are allergic to any ingredient in Papain/Urea Foam

Contact your doctor or health care provider right away if any of these apply to you.



Before using Papain/Urea Foam:


Some medical conditions may interact with Papain/Urea Foam. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

Some MEDICINES MAY INTERACT with Papain/Urea Foam. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Hydrogen peroxide or medicines containing silver, lead, or mercury because they may decrease Papain/Urea Foam's effectiveness

This may not be a complete list of all interactions that may occur. Ask your health care provider if Papain/Urea Foam may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Papain/Urea Foam:


Use Papain/Urea Foam as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Cleanse the affected area with saline or another mild wound cleansing solution each time the dressing is changed. Do not use hydrogen peroxide.

  • Shake well before each use.

  • You must prime the pump before you use it for the first time. Hold the can upright, pointed away from yourself and others. Push down the actuator until the foam begins to come out.

  • The spray canister will work best if you hold it upright while you apply Papain/Urea Foam; however, you may hold the canister at an angle if necessary.

  • Apply Papain/Urea Foam directly onto the wound or onto a secondary dressing as directed by your doctor.

  • Apply Papain/Urea Foam in a single layer as directed by your doctor. Completely cover the wound with medicine. Cover with appropriate dressing (eg, bandages) and secure into place.

  • Wipe the nozzle with clean gauze after each use.

  • Change wound dressings according to the schedule set by your doctor.

  • If irritation occurs, talk with your doctor about changing the dressings more often.

  • Protect the normal skin around the wound with a skin protectant as directed by your doctor.

  • If you miss a dose of Papain/Urea Foam, use it as soon as you remember. Continue to use it as directed by your doctor.

Ask your health care provider any questions you may have about how to use Papain/Urea Foam.



Important safety information:


  • Papain/Urea Foam is for external use only. Do not get it in your eyes, nose, or mouth. If you get it in any of these areas, rinse right away with cool water.

  • Do not puncture, break, or burn the canister, even if it appears to be empty.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Papain/Urea Foam while you are pregnant. It is not known if Papain/Urea Foam is found in breast milk. If you are or will be breast-feeding while you use Papain/Urea Foam, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Papain/Urea Foam:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Mild skin irritation; temporary burning sensation.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); severe or persistent skin irritation.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Papain/Urea side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Papain/Urea Foam:

Store Papain/Urea Foam upright, in a cool place, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat and direct sunlight. Avoid temperatures above 120 degrees F (49 degrees C). Do not puncture, break, or burn the canister even if it appears to be empty. Do not freeze. Keep Papain/Urea Foam out of the reach of children and away from pets.


General information:


  • If you have any questions about Papain/Urea Foam, please talk with your doctor, pharmacist, or other health care provider.

  • Papain/Urea Foam is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Papain/Urea Foam. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Papain/Urea resources


  • Papain/Urea Side Effects (in more detail)
  • Papain/Urea Use in Pregnancy & Breastfeeding
  • Papain/Urea Drug Interactions
  • Papain/Urea Support Group
  • 1 Review for Papain/Urea - Add your own review/rating


Compare Papain/Urea with other medications


  • Burns, External
  • Dermatologic Lesion
  • Wound Cleansing

Abstral Sublingual Tablets





1. Name Of The Medicinal Product



Abstral®


2. Qualitative And Quantitative Composition



Each sublingual tablet contains:



100 micrograms fentanyl (as citrate)



200 micrograms fentanyl (as citrate)



300 micrograms fentanyl (as citrate)



400 micrograms fentanyl (as citrate)



600 micrograms fentanyl (as citrate)



800 micrograms fentanyl (as citrate)



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Sublingual tablet



100 microgram sublingual tablet is a white round tablet



200 microgram sublingual tablet is a white oval-shaped tablet



300 microgram sublingual tablet is a white triangle-shaped tablet



400 microgram sublingual tablet is a white diamond-shaped tablet



600 microgram sublingual tablet is a white “D”-shaped tablet



800 microgram sublingual tablet is a white capsule-shaped tablet



4. Clinical Particulars



4.1 Therapeutic Indications



Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.



4.2 Posology And Method Of Administration



Abstral should only be administered to patients who are considered tolerant to their opioid therapy for persistent cancer pain. Patients can be considered opioid tolerant if they take at least 60 mg oral morphine per day, 25 micrograms transdermal fentanyl per hour, or an equianalgesic dose of another opioid for a week or longer.



Abstral sublingual tablets should be administered directly under the tongue at the deepest part. Abstral sublingual tablets should not be swallowed, but allowed to completely dissolve in the sublingual cavity without chewing or sucking. Patients should be advised not to eat or drink anything until the sublingual tablet is completely dissolved.



In patients who have a dry mouth water may be used to moisten the buccal mucosa before taking Abstral.



Dose titration:



The object of dose titration is to identify an optimal maintenance dose for ongoing treatment of breakthrough pain episodes. This optimal dose should provide adequate analgesia with an acceptable level of adverse reactions.



The optimal dose of Abstral will be determined by upward titration, on an individual patient basis. Several doses are available for use during the dose titration phase. The initial dose of Abstral used should be 100 micrograms, titrating upwards as necessary through the range of available dosage strengths.



Patients should be carefully monitored until an optimal dose is reached.



Switching from other fentanyl containing products to Abstral must not occur at a 1:1 ratio because of different absorption profiles. If patients are switched from another fentanyl containing product, a new dose titration with Abstral is required.



The following dose regimen is recommended for titration, although in all cases the physician should take into account the clinical need of the patient, age and concomitant illness.



All patients must start therapy with a single 100 microgram sublingual tablet. If adequate analgesia is not obtained within 15-30 minutes of administration of a single sublingual tablet, a supplemental (second) 100 microgram sublingual tablet may be administered. If adequate analgesia is not obtained within 15-30 minutes of the first dose, an increase in dose to the next highest tablet strength should be considered for the next episode of breakthrough pain. (Refer to figure below). Dose escalation should continue in a stepwise manner until adequate analgesia is achieved. The dose strength for the supplemental (second) sublingual tablet should be increased from 100 to 200 micrograms at doses of 400 micrograms and higher. This is illustrated in the schedule below. No more than two (2) sublingual tablets should be administered for a single episode of breakthrough pain during this titration phase.




















Strength (micrograms) of first sublingual tablet per episode of breakthrough pain




Strength (micrograms) of supplemental (second) sublingual tablet to be taken 15-30 minutes after first tablet, if required




100




100




200




100




300




100




400




200




600




200




800




-



If adequate analgesia is achieved at the higher dose, but undesirable effects are considered unacceptable, an intermediate dose (using the 100 microgram sublingual tablet where appropriate) may be administered.



Doses higher than 800 micrograms have not been evaluated in clinical studies.



In order to minimise the risk of opioid–related adverse reactions and to identify the appropriate dose, it is imperative that patients be monitored closely by health professionals during the titration process.



Maintenance therapy:



Once an appropriate dose has been established, which may be more than one tablet, patients should be maintained on this dose and should limit consumption to a maximum of four Abstral doses per day.



Dose re-adjustment:



If the response (analgesia or adverse reactions) to the titrated Abstral dose markedly changes, an adjustment of dose may be necessary to ensure that an optimal dose is maintained.



If more than four episodes of breakthrough pain are experienced per day over a period of more than four consecutive days, then the dose of the long acting opioid used for persistent pain should be re-evaluated. If the long acting opioid or dose of long acting opioid is changed the Abstral dose should be re-evaluated and re-titrated as necessary to ensure the patient is on an optimal dose.



It is imperative that any dose re-titration of any analgesic is monitored by a health professional.



Discontinuation of therapy:



For patients no longer requiring any opioid therapy, the Abstral dose should be taken into consideration before a gradual downward titration of opioids to minimise possible withdrawal effects.



In patients who continue to take their chronic opioid therapy for persistent pain but no longer require treatment for breakthrough pain, Abstral therapy may usually be discontinued immediately.



Use in children and adolescents:



Abstral must not be used in patients less than 18 years of age due to a lack of data on safety and efficacy.



Use in elderly patients



Dose titration needs to be approached with particular care and patients observed carefully for signs of fentanyl toxicity (see section 4.4).



Use in patients with renal and hepatic impairment



Patients with kidney or liver dysfunction should be carefully observed for signs of fentanyl toxicity during the Abstral titration phase (see section 4.4).



4.3 Contraindications



Hypersensitivity to the active substance or to any of the excipients.



Opioid-naïve patients because of the risk of life-threatening respiratory depression.



Severe respiratory depression or severe obstructive lung conditions.



4.4 Special Warnings And Precautions For Use



Patients and their carers must be instructed that Abstral contains an active substance in an amount that can be fatal to a child, and therefore to keep all tablets out of the reach and sight of children.



Due to the potentially serious undesirable effects that can occur when taking an opioid therapy such as Abstral, patients and their carers should be made fully aware of the importance of taking Abstral correctly and what action to take should symptoms of overdose occur.



Before Abstral therapy is initiated, it is important that the patient's long-acting opioid treatment used to control their persistent pain has been stabilised.



Upon repeated administration of opioids such as fentanyl, tolerance and physical and/or psychological dependence may develop. Iatrogenic addiction following therapeutic use of opioids is rare.



In common with all opioids, there is a risk of clinically significant respiratory depression associated with the use of Abstral. Particular caution should be exercised during dose titration with Abstral in patients with chronic obstructive pulmonary disease or other medical conditions predisposing them to respiratory depression (e.g. myasthenia gravis) because of the risk of further respiratory depression, which could lead to respiratory failure.



Abstral should only be administered with extreme caution in patients who may be particularly susceptible to the intracranial effects of hyperkapnia, such as those showing evidence of raised intracranial pressure, reduced consciousness, coma or brain tumours. In patients with head injuries, the clinical course may be masked by the use of opioids. In such a case, opioids should be used only if absolutely necessary.



Intravenous fentanyl has been shown to cause bradycardia. Abstral should be used with caution in patients with bradyarrhythmias.



Data from intravenous studies with fentanyl suggest that elderly patients may have reduced clearance, a prolonged half-life and they may be more sensitive to the active substance than younger patients. Elderly, cachectic, or debilitated patients should be observed carefully for signs of fentanyl toxicity and the dose reduced if necessary.



Abstral should be administered with caution to patients with liver or kidney dysfunction, especially during the titration phase. The use of Abstral in patients with hepatic or renal impairment may increase the bioavailability of fentanyl and decrease its systemic clearance, which could lead to accumulation and increased and prolonged opioid effects.



Care should be taken in treating patients with hypovolaemia and hypotension.



Abstral has not been studied in patients with mouth wounds or mucositis. There may be a risk of increased systemic drug exposure in such patients and therefore extra caution is recommended during dose titration.



There should be no noticeable effects on cessation of treatment with Abstral, but possible symptoms of withdrawal are anxiety, tremor, sweating, paleness, nausea and vomiting.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Fentanyl is metabolised by CYP3A4. Active substances that inhibit CYP3A4 activity such as macrolide antibiotics (e.g. erythromycin), azole antifungal agents (e.g. ketoconazole, itraconazole) or certain protease inhibitors (e.g. ritonavir) may increase the bioavailability of fentanyl by decreasing its systemic clearance, potentially enhancing or prolonging opioid effects. Grapefruit juice is also known to inhibit CYP3A4. Fentanyl should therefore be given to patients with caution if administered concomitantly with CYP3A4 inhibitors.



Concomitant use of other CNS depressants, such as other morphine derivatives (analgesics and antitussives), general anaesthetics, skeletal muscle relaxants, sedative antidepressants, sedative H1 antihistamines, barbiturates, anxiolytics (ie benzodiazepines), hypnotics, antipsychotics, clonidine and related substances may produce increased CNS depressant effects. Respiratory depression, hypotension and profound sedation may occur.



Alcohol potentiates the sedative effects of morphine-based analgesics, therefore concomitant administration of alcoholic beverages or medicinal products containing alcohol with Abstral is not recommended.



Abstral is not recommended for use in patients who have received monoamine oxidase (MAO) inhibitors within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.



The concomitant use of partial opioid agonists/antagonists (e.g. buprenorphine, nalbuphine, pentazocine) is not recommended. They have high affinity to opioid receptors with relatively low intrinsic activity and therefore partially antagonise the analgesic effect of fentanyl and may induce withdrawal symptoms in opioid dependent patients.



4.6 Pregnancy And Lactation



The safety of fentanyl in pregnancy has not been established. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Fentanyl should only be used during pregnancy when clearly necessary.



Long-term treatment during pregnancy may cause withdrawal symptoms in the newborn infant.



Fentanyl should not be used during labour and delivery (including caesarean section) since fentanyl crosses the placenta and may cause respiratory depression in the foetus or in the newborn infant.



Fentanyl is excreted into breast milk and may cause sedation and respiratory depression in the breast-fed child. Fentanyl should only be used by breast-feeding women if the benefits clearly outweigh the potential risks for both mother and child.



4.7 Effects On Ability To Drive And Use Machines



No studies on the effects on the ability to drive and use machines have been performed.



However, fentanyl may impair the mental or physical ability to perform potentially hazardous tasks such as driving or operating machinery. Patients should be advised not to drive or operate machinery if they become dizzy or drowsy or experience blurred or double vision while taking Abstral.



4.8 Undesirable Effects



Undesirable effects typical of opioids are to be expected with Abstral; they tend to decrease in intensity with continued use. The most serious potential adverse reactions associated with opioid use are respiratory depression (which could lead to respiratory arrest), hypotension and shock. Other very commonly reported adverse reactions include: nausea, vomiting, constipation, headache, somnolence/fatigue and dizziness.



Adverse reactions from clinical studies with Abstral in patients and volunteers, with a suspected relationship to treatment, are listed below by system organ class and frequency (very common



Nervous system disorders



Very common: Dizziness, somnolence, headache



Common: Vasovagal reaction, hypoaesthesia, paraesthesia, hyperacusis



Eye disorders



Common: Vision abnormal



Respiratory, thoracic and mediastinal disorders



Common: Respiratory depression, rhinitis, pharyngitis



Gastrointestinal disorders



Very common: Nausea



Common: Vomiting, abdominal pain, diarrhoea, constipation, stomach discomfort, dyspepsia, dry mouth



Skin and subcutaneous tissue disorders



Common: Rash, pruritus



Vascular disorders



Common: Orthostatic hypotension, flushing, hot flush



General disorders and administration site conditions



Very common: Fatigue



Common: Asthenia, application site irritation



Psychiatric disorders



Common: Depression, anorexia, concentration impaired, euphoria



All the above adverse reactions were reported in opioid naïve volunteers administered with Abstral. Patients (n=23) treated with Abstral only experienced dizziness, nausea and vomiting.



The following adverse reactions associated with other medicinal products containing fentanyl have also been reported (very common



Cardiac disorders



Uncommon: Bradycardia, tachycardia, hypertension



Very rare: Arrhythmias



Nervous system disorders



Common: Myoclonus, insomnia, taste disorders



Uncommon: Abnormal gait/coordination, vertigo, amnesia, speech disorders, tremor



Respiratory thoracic and mediastinal disorders



Uncommon: Hypoventilation, asthma, dyspnoea,



Very rare: Apnoea, haemoptysis



Gastrointestinal disorders



Common: Gastro-intestinal occlusion, dysphagia, mouth ulcers/stomatitis, tongue disorder



Uncommon: Enlarged abdomen, flatulence, thirst



Rare: Hiccups



Renal and urinary disorders



Uncommon: Urinary retention, change in urinary frequency



Very rare: Bladder spasm, oliguria



Skin and subcutaneous tissue disorders



Very common: Sweating



Injury, poisoning and procedural complications



Common: Accidental injuries



Vascular disorders



Common: Vasodilation



General disorders and administration site conditions



Uncommon: Malaise



Psychiatric disorders



Common: Hallucinations, confusion, anxiety, nervousness, abnormal thinking, abnormal dreams



Uncommon: Agitation, depersonalisation, emotional lability



4.9 Overdose



The symptoms of fentanyl overdose are an extension of its pharmacological actions, the most serious effect being respiratory depression, which may lead to respiratory arrest.



Management of opioid overdose in the immediate term includes removal of any remaining Abstral sublingual tablets from the mouth, physical and verbal stimulation of the patient and an assessment of the level of consciousness. A patent airway should be established and maintained. If necessary an oropharyngeal airway or endotracheal tube should be inserted, oxygen administered and mechanical ventilation initiated, as appropriate. Adequate body temperature and parenteral fluid intake should be maintained.



For the treatment of accidental overdose in opioid-naïve individuals, naloxone or other opioid antagonists should be used as clinically indicated and in accordance with their Summary of Product Characteristics. Repeated administration of the opioid antagonist may be necessary if the duration of respiratory depression is prolonged.



Care should be taken when using naloxone or other opioid antagonists to treat overdose in opioid-maintained patients, due to the risk of precipitating an acute withdrawal syndrome.



If severe or persistent hypotension occurs, hypovolaemia should be considered, and the condition should be managed with appropriate parenteral fluid therapy.



Muscle rigidity interfering with respiration has been reported with fentanyl and other opioids. In this situation, endotracheal intubation, assisted ventilation and administration of opioid antagonists as well as muscle relaxants may be requested.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Phenylpiperidine derivatives.



ATC code: N02AB03



Fentanyl is a potent µ-opioid analgesic with rapid onset of analgesia and short duration of action. Fentanyl is approximately 100-fold more potent than morphine as an analgesic. Secondary effects of fentanyl on central nervous system (CNS), respiratory and gastro-intestinal function are typical of opioid analgesics and are considered to be class effects.



The analgesic effects of fentanyl are related to the blood level of the active substance; in opioid-naïve patients, minimum effective analgesic serum concentrations of fentanyl range from 0.3-1.2 ng/ml, while blood levels of 10-20 ng/ml produce surgical anaesthesia and profound respiratory depression.



In patients with chronic cancer pain on stable maintenance doses of opioids, statistically significant improvement in pain intensity difference was seen with Abstral versus placebo from 10 minutes after administration onwards (see figure 1 below), with a significantly lower need for rescue analgesic therapy.



Figure 1 Mean Pain Intensity Difference from baseline (± SE) for Abstral Compared with Placebo (measured by a 0-10 Likert scale)





The safety and efficacy of Abstral have been evaluated in patients taking the drug at the onset of the breakthrough pain episode. Pre-emptive use of Abstral for predictable pain episodes was not investigated in the clinical trials.



Fentanyl, in common with all µ-opioid receptor agonists, produces dose dependent respiratory depression. This risk is higher in opioid-naïve subjects than in patients experiencing severe pain or receiving chronic opioid therapy. Long-term treatment with opioids typically leads to development of tolerance to their secondary effects.



While opioids generally increase the tone of urinary tract smooth muscle, the net effect tends to be variable, in some cases producing urinary urgency, in others, difficulty in urination.



Opioids increase the tone and decrease the propulsive contractions of the smooth muscle of the gastrointestinal tract leading to a prolongation in gastrointestinal transit time, which may be responsible for the constipating effect of fentanyl.



5.2 Pharmacokinetic Properties



Fentanyl is a highly lipophilic drug absorbed very rapidly through the oral mucosa and more slowly through the gastrointestinal tract. Orally administered fentanyl undergoes pronounced hepatic and intestinal first pass effects.



Abstral is a quick dissolving sublingual tablet formulation. Rapid absorption of fentanyl occurs over about 30 minutes following administration of Abstral. The bioavailability of Abstral has not been studied but is estimated to be about 70%. Mean maximal plasma concentrations of fentanyl range from 0.2 to 1.3 ng/ml (after administration of 100 to 800 µg Abstral) and are reached within 22.5 to 240 minutes.



About 80-85% of fentanyl is bound by plasma proteins, mainly α1-glycoprotein and to a lesser extent albumin and lipoprotein. The volume of distribution of fentanyl at steady state is about 3-6 l/kg.



Fentanyl is metabolised primarily via CYP3A4 to a number of pharmacologically inactive metabolites, including norfentanyl. Within 72 hours of intravenous fentanyl administration around 75% of the dose is excreted into the urine, mostly as metabolites, with less than 10% as unchanged drug. About 9% of the dose is recovered in the faeces, primarily as metabolites. Total plasma clearance of fentanyl is about 0.5 l/h/kg. After Abstral administration, the main elimination half-life of fentanyl is about 7 hours (range 3-12.5 hours) and the terminal half-life is about 20 hours (range 11.5-25 hours).



The pharmacokinetics of Abstral have been shown to be dose proportional over the dose range of 100 to 800 µg.



Renal/hepatic impairment



Impaired hepatic or renal function could cause increased serum concentrations. Elderly, cachectic or generally impaired patients may have a lower fentanyl clearance, which could cause a longer terminal half-life for the compound (see sections 4.2 and 4.4).



5.3 Preclinical Safety Data



Safety pharmacology and repeated dose toxicity data reveal no special hazard for humans that is not already covered by other sections of this SPC. Animal studies have shown reduced fertility and increased mortality in rat foetuses. Teratogenic effects have, however, not been demonstrated.



Mutagenicity testing in bacteria and in rodents yielded negative results. Like other opioids fentanyl showed mutagenic effects in vitro in mammalian cells. A mutagenic risk with therapeutic use seems unlikely since effects were induced only at very high concentrations.



Long-term carcinogenicity studies have not been performed.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Mannitol (E421)



Silicified microcrystalline cellulose



Croscarmellose sodium



Magnesium stearate



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



2 years



6.4 Special Precautions For Storage



Do not store above 25°C.



Store in the original blister package in order to protect from moisture.



6.5 Nature And Contents Of Container



Abstral sublingual tablets are packaged in child resistant blisters of OPA/Aluminium/PVC pockets with paper/polyester/Aluminium lidding contained in a cardboard outer carton. The packaging is colour-coded for each Abstral sublingual tablet strength.



Pack size: Packs of 10 or 30 sublingual tablets. Not all pack sizes may be marketed



6.6 Special Precautions For Disposal And Other Handling



Waste material should be disposed of safely. Patients/carers should be encouraged to return any unused product to the Pharmacy, where it should be disposed of in accordance with national and local requirements.



7. Marketing Authorisation Holder



ProStrakan Ltd



Galabank Business Park



Galashiels



TD1 1QH



United Kingdom



8. Marketing Authorisation Number(S)



Abstral 100 microgram sublingual tablets: PL 16508/0030



Abstral 200 microgram sublingual tablets: PL 16508/0031



Abstral 300 microgram sublingual tablets: PL 16508/0032



Abstral 400 microgram sublingual tablets: PL 16508/0033



Abstral 600 microgram sublingual tablets: PL 16508/0034



Abstral 800 microgram sublingual tablets: PL 16508/0035



9. Date Of First Authorisation/Renewal Of The Authorisation



19/09/2008



10. Date Of Revision Of The Text



17/02/2010



LEGAL CATEGORY


CD (Sch2), POM




Saturday, 31 March 2012

Zoladex


Generic Name: goserelin (Subcutaneous route)

goe-se-REL-in

Commonly used brand name(s)

In the U.S.


  • Zoladex

Available Dosage Forms:


  • Implant

Therapeutic Class: Antineoplastic Agent


Pharmacologic Class: Luteinizing Hormone Releasing Hormone Agonist


Uses For Zoladex


Goserelin is a hormone similar to the one normally released from the hypothalamus gland in the brain. It is used to treat a number of medical problems. These include:


  • Cancer of the prostate in men

  • Cancer of the breast in women if it develops before or around the time of menopause

  • Endometriosis, a painful condition caused by extra tissue growing inside or outside of the uterus, and

  • Thinning of the lining of the uterus before surgery on the uterus.

When given regularly as an implant, goserelin works every day to decrease the amount of estrogen and testosterone in the blood.


Reducing the amount of estrogen in the body is one way of treating endometriosis and cancer of the breast, and can help thin the uterus lining before surgery. Goserelin prevents the growth of tissue associated with endometriosis in adult women during treatment and for up to 6 months after treatment is discontinued.


Reducing the amount of testosterone in the body is one way of treating cancer of the prostate.


Suppressing estrogen can thin the bones or slow their growth. This is a problem for adult women whose bones are no longer growing like the bones of children. This is why goserelin is used only for up to 6 months in adult women treated for endometriosis.


This medicine is to be given only by or under the supervision of your doctor.


Before Using Zoladex


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies have not been performed on the relationship of age to the effects of goserelin in the pediatric population. Safety and efficacy have not been established.


Geriatric


Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of goserelin in elderly men. However, safety and efficacy have not been established for elderly women.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersXStudies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities. This drug should not be used in women who are or may become pregnant because the risk clearly outweighs any possible benefit.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.


Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Alcohol abuse or

  • Osteoporosis, family history of or

  • Tobacco cigarette smoking—May increase risk for osteoporosis (thinning of the bones).

  • Diabetes or

  • Hypercalcemia (high calcium in the blood) or

  • Hyperglycemia (high blood sugar)—Use with caution. May make these conditions worse.

  • Nerve problems caused by bone lesions in the spine (in treatment of cancer of the prostate) or

  • Problems in passing urine (in treatment of cancer of the prostate)—Conditions may get worse for a short time after goserelin treatment is started.

Proper Use of Zoladex


A nurse or other trained health professional will give you this medicine. This medicine is given as a shot under your skin near your stomach. This medicine may be given once every 28 days or once every 3 months. Your schedule depends on the reason you are using this medicine. To stay on the right schedule with the medicine, make sure you keep all appointments.


It is very important that you continue to receive the medicine, even after you begin to feel better.


Precautions While Using Zoladex


It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly and to check for unwanted effects.


For female patients: You should not receive this medicine if you are pregnant or may become pregnant. Using this medicine while you are pregnant can harm your unborn baby. Your birth control pills may not work as well while you are receiving this medicine. Use a nonhormonal form of birth control together with your pills to keep from getting pregnant while you are receiving this medicine and for at least 12 weeks after treatment. Nonhormonal birth control includes vaginal spermicides, condoms, diaphragms, and cervical caps. If you think you have become pregnant while using the medicine, tell your doctor right away.


For female patients: During the time you are receiving goserelin, your menstrual period may not be regular or you may not have a menstrual period at all. This is to be expected when being treated with this medicine. If regular menstrual periods continue during treatment or do not begin within 2 to 3 months after you stop using this medicine, check with your doctor.


For male patients: This medicine may affect blood sugar levels. If you are diabetic and notice a change in the results of your blood or urine sugar tests, check with your doctor.


When you first start using this medicine for cancer treatment, some of your symptoms might get worse for a short time. You might also have new symptoms. You might have bone pain, back pain, or trouble urinating. These symptoms should improve within a few weeks. Tell your doctor if you have any new symptoms or your symptoms get worse.


This medicine can cause decreases in bone mineral density, which may lead to osteoporosis or weakened bones. Talk with your doctor about how this risk will affect you.


This medicine may cause a serious type of allergic reaction called anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Call your doctor right away if you have a rash; itching; hoarseness; trouble breathing; trouble swallowing; or any swelling of your hands, face, or mouth while you are using this medicine.


Before you have any medical tests, tell the medical doctor in charge that you are using this medicine. The results of some tests may be affected by this medicine.


Zoladex Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


For all adultsLess common
  • Fast or irregular heartbeat

Rare
  • Bone, muscle, or joint pain

  • changes in skin color of the face

  • fainting

  • fast or irregular breathing

  • numbness or tingling of the hands or feet

  • puffiness or swelling of the eyelids or around the eyes

  • shortness of breath

  • skin rash, hives, or itching

  • sudden, severe decrease in blood pressure and collapse

  • tightness in the chest or wheezing

  • troubled breathing

For females onlyRare
  • Anxiety

  • deepening of voice

  • increased hair growth

  • mental depression

  • mood changes

  • nervousness

For males onlyRare
  • Pains in the chest

  • pain in the groin or legs (especially in the calves of the legs)

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


For all adultsMore common
  • Sudden sweating and feelings of warmth (also called hot flashes)

Less common
  • Blurred vision

  • burning, itching, redness, or swelling at the place of injection

  • decreased interest in sexual intercourse

  • dizziness

  • headache

  • nausea or vomiting

  • swelling and increased tenderness of the breasts

  • swelling of the feet or lower legs

  • trouble with sleeping

  • weight gain

For females onlyMore common
  • Light, irregular vaginal bleeding

  • stopping of menstrual periods

Less common
  • Burning, dryness, or itching of the vagina

  • pelvic pain

For males onlyLess common
  • Bone pain

  • constipation

  • decreased size of the testicles

  • inability to have or keep an erection

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Zoladex side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Zoladex resources


  • Zoladex Side Effects (in more detail)
  • Zoladex Use in Pregnancy & Breastfeeding
  • Zoladex Drug Interactions
  • Zoladex Support Group
  • 8 Reviews for Zoladex - Add your own review/rating


  • Zoladex Prescribing Information (FDA)

  • Zoladex Monograph (AHFS DI)

  • Zoladex MedFacts Consumer Leaflet (Wolters Kluwer)

  • Zoladex Consumer Overview



Compare Zoladex with other medications


  • Bleeding Disorder
  • Breast Cancer, Palliative
  • Endometriosis
  • Prostate Cancer

Sunday, 25 March 2012

estradiol and medroxyprogesterone


Generic Name: estradiol and medroxyprogesterone (ess tra DY ol and med ROX ee pro JESS te role)

Brand Names: Lunelle


What is estradiol and medroxyprogesterone?

Estradiol and medroxyprogesterone contains a combination of female hormones that prevent ovulation (the release of an egg from an ovary). This medication also causes changes in your cervical mucus and uterine lining, making it harder for sperm to reach the uterus and harder for a fertilized egg to attach to the uterus.


Estradiol and medroxyprogesterone is used as contraception to prevent pregnancy.


Estradiol and medroxyprogesterone may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about estradiol and medroxyprogesterone?


Do not use birth control injections if you are pregnant or if you have recently had a baby. Do not use this medication if you have any of the following conditions: a history of stroke or blood clot, circulation problems (especially if caused by diabetes), a hormone-related cancer such as breast or uterine cancer, abnormal vaginal bleeding, liver disease or liver cancer, severe high blood pressure, migraine headaches, a heart valve disorder, or a history of jaundice caused by birth control pills.

You may need to use back-up birth control, such as condoms or a spermicide, when you first start using this medication. Follow your doctor's instructions.


Using hormones can increase your risk of blood clots, stroke, or heart attack, especially if you smoke and are older than 35.

Some drugs can make birth control injections less effective, which may result in pregnancy. Tell your doctor about all the prescription and over-the-counter medications you use, including vitamins, minerals and herbal products. Do not start using a new medication without telling your doctor.


What should I discuss with my healthcare provider before using estradiol and medroxyprogesterone?


This medication can cause birth defects. Do not use if you are pregnant. Tell your doctor right away if you become pregnant, or if you miss two menstrual periods in a row. If you have recently had a baby, wait at least 4 weeks before using birth control injections (6 weeks if you are breast-feeding). Do not use this medication if you have:

  • a history of a stroke or blood clot;




  • circulation problems (especially if caused by diabetes);




  • a hormone-related cancer such as breast or uterine cancer;




  • abnormal vaginal bleeding;




  • liver disease or liver cancer;




  • severe high blood pressure;




  • severe migraine headaches;




  • a heart valve disorder; or




  • a history of jaundice caused by birth control pills.



Before using this medication, tell your doctor if you have any of the following conditions. You may need a dose adjustment or special tests to safely take birth control hormones.



  • high blood pressure, heart disease, congestive heart failure, angina (chest pain), or a history of heart attack;




  • high cholesterol or if you are overweight;




  • kidney disease;




  • a history of depression;




  • gallbladder disease;




  • diabetes;




  • seizures or epilepsy;




  • a history of irregular menstrual cycles; or




  • a history of fibrocystic breast disease, lumps, nodules, or an abnormal mammogram.




The hormones in this medication can pass into breast milk and may harm a nursing baby. This medication may also slow breast milk production. Do not use if you are breast-feeding a baby.

How is estradiol and medroxyprogesterone used?


This medication is given as an injection into a muscle in your upper arm, thigh, or buttocks. You will receive this injection in your doctor's office or other clinic setting. Before receiving your first injection, tell your doctor about all other forms of birth control you have used within the past 7 days.


The first injection of this medication is given during the first 5 days of a normal menstrual period, or within 5 days after undergoing a complete first-trimester abortion.


After your first injection, you will need to receive monthly injections every 28 to 30 days to assure prevention of pregnancy. Do not allow more than 33 days to pass between injections, even if your menstrual period has started later than expected.


Tell your doctor if your period has not started by the time you are due for your monthly injection.

If you need to have any type of medical tests or surgery, or if you will be on bed rest, you may need to stop using this medication for a short time. Any doctor or surgeon who treats you should know that you are using birth control injections.


Your doctor will need to see you on a regular basis while you are using this medication. Do not miss any appointments.


What happens if I miss a dose?


Missing a monthly injection increases your risk of becoming pregnant. Call your doctor for instructions if you miss an appointment for your injection.


What happens if I overdose?


Seek emergency medical attention if you think you have received too much of this medicine. Overdose symptoms may include nausea, vomiting, and vaginal bleeding.


What should I avoid while using estradiol and medroxyprogesterone?


Do not smoke while using birth control injections, especially if you are older than 35. Smoking can increase your risk of blood clots, stroke, or heart attack caused by birth control pills.

Birth control injections will not protect you from sexually transmitted diseases--including HIV and AIDS. Using a condom is the only way to protect yourself from these diseases.


Estradiol and medroxyprogesterone side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any of these serious side effects:

  • sudden numbness or weakness, especially on one side of the body;




  • sudden headache, confusion, pain behind the eyes, problems with vision, speech, or balance;




  • chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;




  • a change in the pattern or severity of migraine headaches;




  • nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);




  • swelling in your hands, ankles, or feet;




  • a breast lump;




  • symptoms of depression (sleep problems, weakness, mood changes); or




  • ongoing pain, bleeding, or other drainage where the shot was given.



Less serious side effects may include:



  • mild nausea, vomiting, bloating, stomach cramps;




  • breast pain, tenderness, or swelling;




  • freckles or darkening of facial skin;




  • increased hair growth, loss of scalp hair;




  • changes in weight or appetite;




  • problems with contact lenses;




  • vaginal itching or discharge;




  • changes in your menstrual periods, decreased sex drive; or




  • headache, nervousness, dizziness, tired feeling.



This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect.


Estradiol and medroxyprogesterone Dosing Information


Usual Adult Dose for Contraception:

0.5 mL administered by intramuscular injection, into the deltoid, gluteus maximus, or anterior thigh. The first injection should be within the first 5 days of the onset of a normal menstrual period, or within 5 days of a complete abortion, but not earlier than 4 weeks postpartum if not breast-feeding, or 6 weeks postpartum if breast-feeding.


What other drugs will affect estradiol and medroxyprogesterone?


Some drugs can make birth control hormones less effective, which may result in pregnancy. Before using birth control pills, tell your doctor if you are using any of the following drugs:



  • phenylbutazone (Azolid, Butazolidin);




  • prednisolone (Orapred);




  • theophylline (Respbid, Theo-Dur);




  • aminoglutethamide (Cytadren);




  • cyclosporine (Neoral, Sandimmune, Gengraf);




  • St. John's wort;




  • antibiotics such as amoxicillin (Augmentin), ampicillin (Omnipen), doxycycline (Doryx, Vibramycin), griseofulvin (Grisactin, Grifulvin V, Fulvicin PG), minocycline (Minocin), penicillin (Veetids, Pen Vee K, Bicillin), rifampin (Rifadin), rifabutin (Mycobutin), tetracycline (Sumycin, Achromycin, Robitet), and others;




  • seizure medicines such as phenytoin (Dilantin), carbamazepine (Tegretol), felbamate (Felbatol), oxcarbazepine (Trileptal), topiramate (Topamax), or primidone (Mysoline);




  • a barbiturate such as amobarbital (Amytal), butabarbital (Butisol), mephobarbital (Mebaral), secobarbital (Seconal), or phenobarbital (Luminal, Solfoton); or




  • HIV medicines such as amprenavir (Agenerase), atazanavir (Reyataz), tipranavir (Aptivus), indinavir (Crixivan), saquinavir (Invirase), lopinavir/ritonavir (Kaletra), fosamprenavir (Lexiva), ritonavir (Norvir), or nelfinavir (Viracept).



This list is not complete and there may be other drugs that can interact with estradiol and medroxyprogesterone. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.



More estradiol and medroxyprogesterone resources


  • Estradiol and medroxyprogesterone Use in Pregnancy & Breastfeeding
  • Estradiol and medroxyprogesterone Drug Interactions
  • Estradiol and medroxyprogesterone Support Group
  • 0 Reviews for Estradiol and medroxyprogesterone - Add your own review/rating


Compare estradiol and medroxyprogesterone with other medications


  • Birth Control


Where can I get more information?


  • Your pharmacist can provide more information about estradiol and medroxyprogesterone.